Research ArticleCORONAVIRUS

Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals

See allHide authors and affiliations

Science Translational Medicine  27 Jan 2021:
Vol. 13, Issue 578, eabd6990
DOI: 10.1126/scitranslmed.abd6990

Article Information

vol. 13 no. 578

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 7, 2020
  • Resubmitted September 7, 2020
  • Accepted for publication December 28, 2020
  • .

Author Information

  1. Sang Il Kim1,2,*,
  2. Jinsung Noh3,*,
  3. Sujeong Kim1,4,
  4. Younggeun Choi1,
  5. Duck Kyun Yoo1,2,4,
  6. Yonghee Lee3,
  7. Hyunho Lee3,
  8. Jongtak Jung5,
  9. Chang Kyung Kang5,
  10. Kyoung-Ho Song5,
  11. Pyoeng Gyun Choe5,
  12. Hong Bin Kim5,
  13. Eu Suk Kim5,
  14. Nam-Joong Kim5,
  15. Moon-Woo Seong6,
  16. Wan Beom Park5,
  17. Myoung-don Oh5,
  18. Sunghoon Kwon3,7,8,9,10, and
  19. Junho Chung1,4,11,
  1. 1Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  2. 2Ischemic/Hypoxic Disease Institute, Seoul National University Medical Research Center, Seoul 03080, Republic of Korea.
  3. 3Department of Electrical and Computer Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  4. 4Department of Biomedical Science, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  5. 5Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  6. 6Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  7. 7Interdisciplinary Program in Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.
  8. 8BK21+ Creative Research Engineer Development for IT, Seoul National University, Seoul 08826, Republic of Korea.
  9. 9Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
  10. 10Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul 08826, Republic of Korea.
  11. 11Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  1. Corresponding author. Email: skwon{at}snu.ac.kr (S. Kwon); jjhchung{at}snu.ac.kr (J.C.)
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: January 2021 to April 2021

AbstractFullPdf
Jan 202122143611038
Feb 202124472362141
Mar 20212243738478
Apr 2021371383120

Stay Connected to Science Translational Medicine

Navigate This Article